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We conducted a phase I/II study to investigate whether the surgical resection after induction chemotherapy with cisplatin and
irinotecan was feasible and could improve the treatment outcome for patients with pathological N2 non-small cell lung cancer.
Fifteen patients with stage IIIA non-small cell lung cancer having mediastinal lymph node metastases proved by
mediastinoscopy were eligible. Both cisplatin (60 mg m
72) and irinotecan (50 mg m
72) were given on days 1 and 8.
Patients received two cycles of chemotherapy after 3–4 weeks interval. Induction was followed by surgical resection in 4–6
weeks. Patients who had documented tumour regression after preoperative chemotherapy received two additional cycles of
chemotherapy and other patients received radiotherapy postoperatively. After the induction chemotherapy, the objective
response rate was 73%. All the 15 patients received surgical resection and complete resection was achieved in 11 (73%)
patients. There was no operation-related death and one death due to radiation pneumonitis during postoperative
radiotherapy. The median time from entry to ﬁnal analysis was 46.5 months, ranging from 22 to 68 months. The 5-year
survival rate was 40% for all the 15 patients and it was 55% for the 11 patients who underwent complete resection. We
conclude that the surgical resection after induction chemotherapy with cisplatin and irinotecan is feasible, and associated with
low morbidity and high respectability.
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The prognosis for non-small-cell lung cancer (NSCLC) with metas-
tases in mediastinal nodes after surgery is generally poor because
distant micrometastases are frequently present. If these nodes are
found before operation by mediastinoscopy and treated with surgi-
cal resection and postoperative irradiation, the 5-year survival is
only approximately 10% (Pearson et al, 1982). Although many
studies have been performed to evaluate adjuvant chemotherapy,
the results of these studies have been disappointing on the whole.
Recently, several neoadjuvant treatment schedules using induction
chemotherapy (Roth et al, 1998; Rosell et al, 1999) or chemora-
diotherapy (Rusch et al, 1993; Albain et al, 1995; Sugarbaker et
al, 1995; Mathisen et al, 1996; Rice et al, 1998) followed by surgical
resection have shown encouraging results.
We have recently reported the results of combination
chemotherapy of cisplatin (CDDP) and irinotecan (CPT-11) for
unresectable NSCLC (Ueoka et al, 1999). The objective response
rate was 76% and the toxicity was manageable. The purpose of this
study was to assess toxicity, response, and survival in patients with
pathological N2, stage IIIA NSCLC who received induction
chemotherapy with CDDP and CPT-11.
MATERIALS AND METHODS
Patient selection
Initial staging evaluation included complete history and physical
examination, a complete blood cell count, standard chemistry
proﬁle, urinalysis, 24-h urine creatinine clearance, electrocardio-
gram, bronchoscopy, arterial blood gas analysis and pulmonary
function test. Pretreatment chest X-ray, bone scan and CT of brain,
chest and abdomen were required to ensure the absence of any
haematogenous dissemination.
Eligibility requirements for entry into the study were as follows:
(1) histologically or cytologically proven NSCLC (excluding
bronchoalveolar carcinoma); (2) no prior chemotherapy, radiother-
apy or surgery; (3) age of 75 years or less; (4) clinical N2, stage
IIIA (T1–3) based on CT scanning; (5) pathological N2 proved
by mediastinoscopy; (6) performance status (PS) of 0–1 on the
Eastern Cooperative Oncology Group (ECOG) scale (Oken et al,
1982); (7) adequate pulmonary function to undergo surgical resec-
tion (predicted postoperative forced expiratory volume in 1 s per
predicted preoperative forced vital capacity 40.3); (8) adequate
functions of the kidney (creatinine clearance 460 ml min
71), liver
(ALT, AST 5twice the upper limit of normal), and bone marrow
(a leukocyte count 54000 ml
71 and a platelet count
5100 000 ml
71); (9) no other primary cancer within the 5 years
before diagnosis and (10) a written form of informed consent.
Lymphadenopathy was initially investigated by CT scanning and
mediastinal lymph nodes larger than 10 mm along their long axis
(except for subcarinal nodes) were deﬁned as metastatic lymph
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www.bjcancer.comnodes (clinical N2). For subcarinal lymph nodes, nodes larger than
10 mm along their short axis were deﬁned as metastatic nodes
(clinical N2). These patients with clinical N2 then underwent a
staging cervical mediastinoscopy with evaluation of bilateral node
stations 2 and 4 and subcarinal station 7 as deﬁned by The Japan
Lung Cancer Society. An anterior mediastinoscopy with biopsy of
station 5 or 6 was not done. Only patients with pathologically
documented N2 (pathological N2) were eligible.
Treatment plan
Planned treatment began with induction chemotherapy. Both
CDDP and CPT-11 were given by 1-h infusion on days 1 and 8.
Patients received two cycles of chemotherapy after 3–4 weeks
interval. CDDP (60 mg m
72) was given with 100 ml of physio-
logical saline just after administration of odansetron (4 mg) or
granisetron (3 mg). CPT-11 (50 mg m
72) dissolved in 300 ml
physiological saline was given after the administration of CDDP.
After administration of CDDP and CPT-11, hydration consisting
of 3000 ml of physiological saline was given. Toxicity was evaluated
according to the criteria of ECOG (Oken et al, 1982). If grade 4
haematological toxicity or grade 3 non-haematological toxicity
such as diarrhoea was observed in the previous course, the dose
of CPT-11 was reduced by 10 mg m
72 in the next cycle. The dose
of CDDP was reduced by 10 mg m
72 for development of grade 4
haematological toxicity or by 30 mg m
72 for development of grade
3 renal toxicity. Before the next course was started, leukocyte and
platelet counts had to be at least 3000 ml
71 or more and
75000 ml
71 or more respectively. If the leukocyte count was
52000 ml
71 or neutrophil count was 51000 ml
71 , granulocyte
colony-stimulating factor (G-CSF) was administered subcuta-
neously at a dose of 50 mgm
72 until recovery.
Two to 4 weeks after the completion of induction chemother-
apy, patients were restaged and evaluated for clinical response by
chest X-ray, bone scan, and CT of brain, chest and abdomen.
Progressive disease was deﬁned as greater than 25% increase in
the sum of the products of the crossed diameters of the primary
lesion over the size present at study entry or the appearance of
new locoregional or metastatic disease. Stable disease was deﬁned
as a change in the size of measured lesions between a 50% reduc-
tion and a 25% increase with no additional disease discovered.
Partial response was deﬁned as a reduction of greater than 50%
in the sum of the products of the crossed diameters of the primary
lesion and the absence of new lesions. Complete response was
deﬁned at the disappearance of all measurable intrathoracic disease.
Patients with progressive disease were taken off study and all other
patients with response or stable disease underwent thoracotomy 4 to
6 weeks after the last dose of chemotherapy. The surgical procedure
was based on the extent of tumour at the time of initial presentation
rather than at the time of thoracotomy. Lobectomy was the preferred
resection; however, if primary tumour invasion required, a sleeve
resection, bilobectomy or pneumonectomy was done. Resection
and reconstruction of the chest wall was also performed if necessary.
A complete ipsilateral superior mediastinal lymphadenectomy was
performed in all cases (resection of ipsilateral nodal stations 1, 2,
3, 4 and 7). For patients with primary lower lobe lesions, stations
8 and 9 lymph nodes were also resected. Patients with primary left
lung lesions also had resection of stations 5 and 6 lymph nodes.
The bronchial stump was covered with pedicled intercostal muscle
or pericardial fat tissue. Complete resection was deﬁned as a surgical
resection in which the tumour and accessible mediastinal lymph
nodes were completely removed, and incomplete resection was
deﬁned as a surgical resection in which the tumour, metastatic
lymph nodes, or both were incompletely removed.
For patients who had documented a tumour reduction of great-
er than 50% after induction chemotherapy, two additional cycles of
chemotherapy using an identical regimen were given starting 4 to 6
weeks after thoracotomy. Other patients received postoperative
radiation therapy, 2.0 Gy a day, to a total dose of 50 Gy as an
option.
Follow-up
After the completion of all treatment, patients were evaluated in an
outpatient clinic every month for a year, and every 3 months there-
after. Chest X-ray was taken at each visit. Bone scan and CT of
brain, chest, and abdomen were required every 6 months for a
year, and yearly thereafter or when clinical signs of recurrence
developed. Recurrences were classiﬁed as locoregional (inside the
ipsilateral thorax), distant (outside the ipsilateral thorax), or both.
Survival curves were constructed using the Kaplan–Meier method.
Survival times were calculated from the date of mediastinoscopy.
Results were analyzed as of 28 February, 2001.
RESULTS
Between June 1995 and April 1999, 411 patients with NSCLC
received surgery in our centre. Among them, 15 patients (3.6%)
with stage IIIA NSCLC having mediastinal lymph node metastases
proved by mediastinoscopy were entered into this clinical trial. The
distribution of patients entered in the trial by years is as follows;
1995, six patients; 1996, three patients; 1997, ﬁve patients; 1999,
one patient. Characteristics of all patients are listed in Table 1.
The mean age was 60 years ranging from 45 to 75. There were
13 men and two women. Histological cell type of the ﬁnal pathol-
ogy specimen showed eight patients had adenocarcinoma, four had
squamous, two had large-cell, and one had adeno-squamous cell
lung cancer. The primary tumour at initial presentation was classi-
ﬁed clinically as T1 in three, T2 in 10 and T3 in two. The diameter
of the primary tumour ranged from 12 to 88 mm with an average
of 43.3 mm. The size of the largest mediastinal lymph node along
its long axis by CT ranged from 10 to 60 mm with an average of
26.1 mm. All patients had histologically proved N2 disease by
cervical mediastinoscopy. Single nodes only were affected in ﬁve
patients and 10 patients were found to have multiple positive
nodes at the time of mediastinoscopy.
Toxicity from induction chemotherapy is summarized in Table
2. Haematological toxicity was generally mild. Two patients devel-
oped grade 4 neutropenia during the ﬁrst cycle of chemotherapy
and one patient during the second cycle. Non-haematological toxi-
city was entirely manageable without treatment interruption
although nausea, vomiting and diarrhoea were experienced by most
patients. There was no evidence of severe pulmonary, cardiac,
hepatic or renal toxicity. Eleven patients (73%) received two cycles
of chemotherapy without dose modiﬁcation and four patients
(27%) required dose modiﬁcation due to toxicity.
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Table 1 Patient characteristics
Number Age (years) Sex Histology TNM
1 49 Male Adenosquamous T2N2M0
2 57 Male Squamous T3N2M0
3 56 Male Adeno T2N2M0
4 61 Male Squamous T3N2M0
5 68 Male Adeno T2N2M0
6 69 Male Adeno T2N2M0
7 59 Male Adeno T2N2M0
8 45 Female Adeno T2N2M0
9 48 Male Squamous T2N2M0
10 54 Male Adeno T1N2M0
11 60 Male Large T2N2M0
12 55 Male Large T1N2M0
13 75 Female Adeno T2N2M0
14 73 Male Adeno T1N2M0
15 71 Male Squamous T2N2M0
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clinical response determination was made on the basis of the
second chest CT scan. At this time, 11 patients (73%) achieved a
partial response and four patients (27%) had stable disease. No
complete responses were seen and no patients had disease progres-
sion.
All the 15 patients underwent thoracotomy 4 to 6 weeks after
the last dose of chemotherapy. Eleven patients (73%) had a
complete surgical resection. Four patients (27%) had an incom-
plete resection (two had subcarinal nodes invading to the carina,
and two had paratracheal nodes invading to the trachea and super-
ior vena cava). No patient had an exploratory thoracotomy. Nine
patients were treated with a lobectomy, three with a bilobectomy,
one with pneumonectomy, one with a sleeve lobectomy and one
with pneumonectomy and chest wall resection. One patient (7%)
developed a bronchopleural ﬁstula and empyema after right upper
lobectomy. This complication was successfully managed by a chest
tube drainage and pleural irrigation. Of note was that the stump of
the bronchus was not covered at resection only in this patient. No
other signiﬁcant postoperative complication was encountered.
Three patients (20%) were judged to have no residual tumour in
the primary site pathologically. Of the three patients, one patient
(7%) had no evidence of tumour in any examined lymph nodes
(T0N0M0) and another had only N1 diseased nodes (T0N1M0).
Therefore, two patients (13%) were downstaged to mediastinal
node negative disease at resection.
Among 11 patients who had shown partial response by induc-
tion chemotherapy, eight patients received two additional cycles
of adjuvant chemotherapy using an identical regimen. Toxicity
ﬁndings during adjuvant chemotherapy were similar to those
during induction. Another three patients (two due to incomplete
resection and one due to chest wall resection) received postopera-
tive radiation therapy to a total dose of 50 Gy. Among four
patients who had shown no response by induction chemotherapy,
two received postoperative radiation therapy, one refused further
treatment, and one did not receive any treatment due to bronchial
ﬁstula.
One right pneumonectomy patient died on postoperative day 74
from radiation pneumonitis which occurred after receiving a total
dose of 20 Gy. This single death (7%) was considered treatment
related.
At the time of ﬁnal data analysis in February 2001, the median
time from entry to ﬁnal analysis for all patients was 46.5 months,
ranging from 22 to 68 months. Median follow-up of patients alive
was 48.6 months. Six patients (40%) were alive, two with recurrent
disease. Of nine (60%) deaths, eight were from recurrent disease
and one was from treatment. Locoregional failure occurred in three
patients (20%) who underwent incomplete resection. Distant
recurrence developed in seven patients (47%).
The projected 5-year Kaplan–Meier overall survival was 40%,
with a median overall survival of 20 months (Figure 1). The 5-year
survival for the 11 patients having complete resection was 55%,
whereas, none of the four patients having incomplete resection
survived for more than 20 months.
DISCUSSION
Operation is accepted as the best therapy for stage I and II non-
small cell lung cancer (NSCLC), achieving cure rates between 40
and 80%. The group of patients with affected ipsilateral mediastinal
lymph nodes represents a challenge. It is critically important to
stage these patients accurately before making treatment decisions.
Although the chest CT scan is valuable to determine the extent
to the primary disease, its assessment of the mediastinal lymph
nodes might be falsely positive in as many as 30% of cases and
falsely negative in 20%. All patients in our series had mediastino-
scopy-positive cancers, which insures the assignment of these
patients to the poor prognosis subgroup in stage IIIA.
There is a growing body of date regarding the multimodality
induction approach to stage IIIA lung cancer. Two recent phase
III trials of induction chemotherapy followed by resection in
patients with stage IIIA disease, including some with T3N0 or
T3N1 disease, have reported an improved survival in combined
modality group (Roth et al, 1998; Rosell et al, 1999). These two
studies lend credence to the concept of induction therapy for stage
IIIA NSCLC. To date, the optimal regimen has yet to be deﬁned
and questions remain regarding whether chemotherapy is better
alone or in combination with radiotherapy. We chose CDDP and
CPT-11 as induction chemotherapeutic regimen on the bases of
our previous experience in treating 17 patients with unresectable
NSCLC (Ueoka et al, 1999). CPT-11 is a semisynthetic derivative
of camptothecin that exerts its cytotoxic activity by inhibiting a
nuclear enzyme topoisomerase I as a novel therapeutic target
(Hsiang and Liu, 1988). The synergistic effect between CDDP
and CPT-11 might be intensiﬁed because these drugs were simul-
taneously given for 2 days within one course. The recommended
dose of CDDP and CPT-11 was determined to be 60 and
50 mg m
72. We avoided concurrent radiation therapy because
chemotherapy with CDDP and CPT-11 plus concurrent radiation
therapy was associated with unacceptable morbidity (Yokoyama
et al, 1998).
The overall morbidity and mortality rates were quite acceptable.
Haematological toxicity was generally mild. Non-haematological
toxicity was entirely manageable without treatment interruption
although nausea, vomiting and diarrhoea were experienced by most
patients. There were no deaths from toxicity during induction
chemotherapy. All patients fully recovered from these toxicities
within 4–6 weeks and were able to receive surgical resection.
Regarding postoperative complications, one patient (7%) devel-
oped a bronchopleural ﬁstula and empyema. This complication
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Table 2 Induction chemotherapy toxicity (n=15)
First cycle Second cycle
Grade 3 Grade 4 Grade 3 Grade 4
Haematological toxicities
Leucocyte 1 0 0 0
Neutrophil 5 2 2 1
Platelet 1 0 0 0
Haemoglobin 1 0 2 0
Non-haematological toxicities
Nausea 3 0 3 0
Vomiting 2 0 2 0
Diarrhoea 1 0 0 0
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Figure 1 The Kaplan–Meier survival curve of all 15 patients. The median
survival is 20 months with a projected survival of 40% at 5 years.
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gation. We elected to cover the bronchial stump with pedicled
viable tissue except this particular patient. One patient died from
radiation pneumonitis after right pneumonectomy. This single
death (7%) was considered treatment related. A 43% mortality
after pneumonectomy was reported in an induction chemora-
diotherapy trial (Fowler et al, 1993).
The objective radiographic response rate of 73% and the resect-
ability of 73% of all eligible patients in this study agree with the
previous trials of induction chemoradiotherapy (Rusch et al, 1993;
Sugarbaker et al, 1995; Mathisen et al, 1996; Rice et al, 1998).
However, pathological sterilization of mediastinal lymph nodes was
seen only in two patients (13%). Induction chemoradiotherapy has
achieved 40–46% incidence of pathological downstaging.
The ultimate test of any induction therapy rests on the survival
rate. Our study includes only 15 patients, however, the median
follow-up of 46.5 months was long enough to assess the long-
term survival rate. The 5-year survival rate of 40% and median
survival of 20 months was comparable to or slightly better than
those seen in other studies that used induction chemoradiother-
apy. The excellent 5-year survival of 55% in 11 patients who
underwent complete resection suggests that complete surgical
resection still play a substantial role on long-term survival in this
stage of disease.
In conclusion, the surgical resection after induction chemother-
apy with CDDP and CPT-11 is feasible, and associated with low
morbidity and high respectability.
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